|
WO2020188049A1
|
|
Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer
|
|
WO2020049124A1
|
|
Inhibitors of glucose transporters (gluts)
|
|
US2020031794A1
|
|
4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
|
|
WO2019057821A1
|
|
Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
|
|
EP3613738A1
|
|
4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
|
|
WO2015181272A1
|
|
Rab geranylgeranyl transferase inhibitors
|
|
CA2826464A1
|
|
Pharmaceutically active disubstituted triazine derivatives
|
|
CN103562184A
|
|
Pharmaceutically active disubstituted pyridine derivatives
|
|
EP2634189A1
|
|
Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
|
|
EP2634190A1
|
|
Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
|
|
DE102011111991A1
|
|
New cyclosporin derivatives
|
|
EP2561867A1
|
|
CDK9 inhibitors in the treatment of midline carcinoma
|
|
EP2562265A1
|
|
Susceptibility to selective CDK9 inhibitors
|
|
EP2423208A1
|
|
Pharmaceutically active compounds as Axl inhibitors
|
